Sanofi $SNY Shares Purchased by Kovitz Investment Group Partners LLC

Kovitz Investment Group Partners LLC boosted its holdings in Sanofi (NASDAQ:SNY) by 294.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 62,859 shares of the company’s stock after purchasing an additional 46,921 shares during the quarter. Kovitz Investment Group Partners LLC’s holdings in Sanofi were worth $3,486,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Accent Capital Management LLC acquired a new position in Sanofi in the first quarter valued at $29,000. Eastern Bank increased its stake in Sanofi by 121.0% during the first quarter. Eastern Bank now owns 548 shares of the company’s stock worth $30,000 after acquiring an additional 300 shares during the last quarter. Golden State Wealth Management LLC increased its stake in Sanofi by 619.3% during the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company’s stock worth $35,000 after acquiring an additional 545 shares during the last quarter. Brentview Investment Management LLC acquired a new stake in Sanofi during the first quarter worth about $42,000. Finally, UMB Bank n.a. increased its stake in Sanofi by 30.7% during the first quarter. UMB Bank n.a. now owns 1,124 shares of the company’s stock worth $62,000 after acquiring an additional 264 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have commented on SNY shares. Wall Street Zen upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Morgan Stanley set a $56.00 price target on Sanofi in a research note on Monday, June 2nd. Guggenheim restated a “buy” rating on shares of Sanofi in a research note on Tuesday, June 3rd. Barclays restated an “overweight” rating on shares of Sanofi in a research note on Wednesday, July 2nd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Sanofi in a research report on Tuesday, August 5th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, Sanofi currently has a consensus rating of “Buy” and a consensus target price of $62.00.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $49.77 on Monday. Sanofi has a 1-year low of $44.73 and a 1-year high of $60.12. The business has a 50-day moving average of $48.57 and a 200-day moving average of $51.81. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94. The company has a market capitalization of $122.21 billion, a price-to-earnings ratio of 11.96, a PEG ratio of 1.19 and a beta of 0.48.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%. The company had revenue of $11.34 billion during the quarter, compared to analysts’ expectations of $9.91 billion. During the same period in the previous year, the company earned $1.73 EPS. Sanofi’s quarterly revenue was down 7.0% on a year-over-year basis. On average, equities analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.